23 results about "Pepsinogen I" patented technology

The invention provides a pepsinogen II determination kit and a quantitative determination method, the kit comprises a reagent R1 and a reagent R2, the reagent R1 comprises a luminous donor molecule labeled pepsinogen II first antibody and a reaction buffer solution; and the R2 reagent comprises a light-emitting receptor molecule labeled pepsinogen II second antibody and a reaction buffer solution. A double-antibody sandwich structure marked by a luminescent donor and a luminescent receptor respectively is adopted, binding and luminescence can be completed in a liquid phase, solid phase coating and subsequent multi-step washing are not needed, real homogeneous detection and one-step incubation are achieved, the operation process is simplified, the detection time is shortened, and a full-automatic platform is adapted; and an improved buffer system can inhibit non-specific adsorption and reduce heterotropism interference such as RF / HAMA, so that the detection accuracy and repeatability are improved.

The invention discloses a kit and a method for detecting pepsin based on polypeptide, and belongs to the technical field of proteomics. The amino acid sequence of the polypeptide is as shown in SEQ ID No. 1. The polypeptide is obtained based on enzymolysis of pepsinogen PGA4 and screening, the polypeptide and isotope labeled polypeptide are utilized to establish a standard curve, a biological sample is further subjected to enzymolysis to obtain a peptide fragment sample, and pepsin in the biological sample can be quantified by detecting the content of the polypeptide in the peptide fragment sample. By utilizing the method disclosed by the invention, the pepsin in the biological sample can be rapidly quantified, so that pathological reflux and physiological reflux are diagnosed and distinguished, and the accuracy rate is high.

The invention relates to a chemiluminescence kit for detecting pepsinogen II. The kit comprises an enzyme marker, a luminescent substrate solution and an anti-interference buffer system, the anti-interference buffer system comprises a nonionic surfactant, animal-derived IgG (immunoglobulin G), an antioxidant and catalase; the chemiluminescence kit also comprises a PG II calibration product and a PG II quality control product. The core active component of the enzyme marker is beta-galactosidase. The enzyme marker further comprises an anti-PG II monoclonal antibody marked by beta-galactosidase, bovine serum albumin, trehalose, cane sugar, MgCl2. 6H2O, sodium chloride, Proclin300 and a phosphate buffer solution. According to the kit, a brand-new anti-interference buffer system is introduced on the basis of a spatial proximity chemiluminescence analysis method, so that the resistance to clinically common interferents (such as hemolysis, lipemia, jaundice and heterotropism antibodies) is remarkably improved, and the detection result is more accurate and reliable.

The invention provides a PGI monoclonal antibody combination for pepsinogen I detection and application thereof, the PGI monoclonal antibody combination for pepsinogen I detection comprises a first antibody and a second antibody, the first antibody comprises a first light chain variable region and a first heavy chain variable region, and the second antibody comprises a second light chain variable region and a second heavy chain variable region. The second antibody comprises a second light chain variable region and a second heavy chain variable region; wherein the amino acid sequence of the first light chain variable region comprises VL-CDR1-3 as shown in SEQ ID NO: 1-3; the amino acid sequence of the first heavy chain variable region comprises VH-CDR1-3 as shown in SEQ ID NO: 4-6; the amino acid sequence of the second light chain variable region comprises VL-CDR1-3 as shown in SEQ ID NO: 7-9; and the amino acid sequence of the second heavy chain variable region comprises VH-CDR1-3 as shown in SEQ ID NO: 10-12. The monoclonal antibody combination can improve the sensitivity and accuracy of in-vitro detection.

The utility model discloses a pepsinogen II detection kit which comprises a heat preservation shell, a refrigeration base movably mounted at the bottom of the heat preservation shell through a second thread, and a temperature conduction mechanism movably inserted into the refrigeration base, and the temperature conducting mechanism is used for rapidly transmitting the refrigeration temperature of the refrigeration base into the heat preservation shell. The pepsinogen II detection kit solves the problems that when an existing pepsinogen II detection kit is used, refrigeration needs to be performed by depending on external refrigeration equipment, so that a detection reagent can be stored for a long time, and the storage temperature of the reagent cannot be guaranteed when the pepsinogen II detection kit is used at high frequency.

The present invention provides antibodies that specifically bind to pepsinogen C and compositions and kits comprising such antibodies. Furthermore, polynucleotides encoding such antibodies, host cells expressing the antibodies, methods of producing such antibodies and diagnostic methods using such antibodies are provided.

The present disclosure provides antibodies that specifically bind to pepsinogen A, as well as compositions and kits comprising such antibodies. Furthermore, provided are polynucleotides encoding such antibodies, host cells expressing the antibodies, methods of producing such antibodies, and diagnostic methods using such antibodies.

The utility model relates to the technical field of kits, in particular to a pepsinogen I determination kit with a quantitative sampling mechanism. According to the technical scheme, the kit comprises a kit body and reagent bottles, a kit cover is installed at the upper end of the kit body, a stabilizing frame is arranged in the kit body, a test tube groove and a reagent groove which are used for storing the reagent bottles and test tubes are formed in the stabilizing frame, the interior of each reagent bottle is divided into quantitative cavities with the same size through a *-shaped partition plate, and sealing stickers are fixed to the upper ends of the quantitative cavities. And a bottle cap is mounted at the upper end of the reagent bottle. The reagent bottle is divided into a plurality of quantitative cavities by utilizing the *-shaped partition plates, during sampling, only a certain quantitative cavity needs to be opened for sampling, the quantitative sampling difficulty is reduced, the reagent bottle and a test tube can be clamped by utilizing dislocation of the movable plates, the stability of the reagent bottle and the test tube is kept, and the safety of storage and transportation is improved.

This application relates to the technical field of bioassay, specifically disclosing a combined detection kit for pepsinogen I and pepsinogen II and its application. The disclosed combined detection kit for pepsinogen I and pepsinogen II includes: a sample pad, a conjugate pad, a coating membrane, and an absorbent pad; the coating membrane is an NC membrane coated with antibody; the conjugate pad is prepared by pretreating and drying a fiber membrane, followed by spraying time-resolved fluorescent microspheres labeled with antibody; the pretreating solution is a solution of pH 8.0-8.4 + 8-12mM BS + 0.8-1.2% BSA + 0.8-1.2% PEG4000 + 0.02-0.03% surfactant + 4-6% sucrose. Using the detection kit and method provided in this application for the combined detection of pepsinogen I / pepsinogen II exhibits high sensitivity, accuracy, and repeatability.

The invention discloses a preparation method and application of recombinant pepsin, and belongs to the technical field of enzyme engineering. The invention mainly aims to provide a method for commercially preparing recombinant pepsin and application of the recombinant pepsin, so that animal-derived pepsin is replaced by the recombinant pepsin to solve the current application problem. Specifically, the method comprises the following steps: introducing a pepsinogen coding gene containing a signal peptide as shown in SEQ ID NO.2 into pichia pastoris host bacteria to obtain recombinant pichia pastoris; performing high-density fermentation on the recombinant pichia pastoris to obtain fermentation liquor containing recombinant pepsinogen; performing ultrafiltration concentration and filter washing dialysis on the fermentation liquor to obtain a zymogen solution, and activating the zymogen solution under an acidic condition to obtain an active recombinant pepsin solution; and purifying the recombinant pepsin solution to obtain the recombinant pepsin. The zymogen produced by the method disclosed by the invention is high in yield, and the pepsin obtained from the zymogen has the same function as the extracted pepsin.

The invention discloses a SrTiO3-In2S3 heterojunction photosensitive material and a sensor and application thereof, the photosensitive material adopts a two-step hydrothermal method to successfully construct an II-type heterojunction, and the separation efficiency of photon-generated carriers is remarkably improved, so that the photocurrent response is enhanced; a photosensitive material is modified on the surface of a tin oxyfluoride electrode to form a composite electrode, then the composite electrode and a micro-fluidic chip construct a micro-fluidic photoelectrochemical immunosensor, and a specific antibody is fixed to serve as a biological recognition element. According to the sensor, trace consumption of samples and reagents is realized, and a controllable reaction environment is provided. When the sensor is used for detecting pepsinogen I, the sensor shows a wide linear range, high sensitivity and excellent selectivity and stability, the lower detection limit is as low as 0.1 pg.mL <-1 >, the upper limit can reach 1 mu g.mL <-1 >, and the sensor has a wide application prospect in the field of clinical disease marker detection.

The utility model belongs to the technical field of serum detection equipment, and particularly relates to serum detection equipment for gastric cancer early screening, which comprises a detection box, a treatment groove and a detection groove are formed in the detection box, a treatment mechanism comprises a treatment box and a pick-and-place assembly, and an extractor and a dilution tube are fixed at the output end of the pick-and-place assembly; the detection mechanism comprises a driving motor, a driving screw rod and a lifting plate, a plurality of placement grooves are formed in the top of the lifting plate, and detection plates are detachably connected into the placement grooves; serum is placed in the treatment box and diluted through the dilution pipe, then the taking and placing assembly drives the suction device to extract a sample, the serum is dropped into the detection hole in the detection plate, the lifting plate and the detection plate are driven by the driving motor to move to a detection area, and the detection area is detected. The detection box is used for detecting pepsinogen I (PGI), pepsinogen II (PGII) and the ratio of PGI to PGII in serum through a chemiluminescence method.

The invention provides a PGII monoclonal antibody combination for pepsinogen II detection and application thereof.The PGII monoclonal antibody combination for pepsinogen II detection comprises a first antibody and a second antibody, the first antibody comprises a first light chain variable region and a first heavy chain variable region, and the second antibody comprises a second light chain variable region and a second heavy chain variable region; the second antibody comprises a second light chain variable region and a second heavy chain variable region. The monoclonal antibody combination can improve the sensitivity and accuracy of in-vitro detection.

The invention discloses a kit for diagnosing inhalation pneumonia and a preparation method thereof, and belongs to the technical field of inhalation pneumonia detection. The kit for diagnosing the inhalation pneumonia comprises a PVC (polyvinyl chloride) bottom plate, a sample pad, a gold mark pad, a nanofiber membrane, a liquid absorption pad and a plastic card shell, a detection line 1, a detection line 2 and a quality control line are fixed on the nanofiber membrane; the detection line 1 and the detection line 2 consist of a colloidal gold labeled pepsinogen I antibody secondary antibody, a colloidal gold labeled pepsinogen II antibody secondary antibody; the preparation method comprises the following steps: under a nitrogen atmosphere, firstly, heating a chloroauric acid aqueous solution to be boiled, quickly adding a trisodium citrate aqueous solution, and boiling; cooling to room temperature, slowly adding an SH-PEG-COOH solution, reacting, standing overnight, centrifuging, washing, and adding a confining liquid to obtain a colloidal gold solution; the kit prepared by the invention has better accuracy and specificity and is convenient to operate.

The invention provides a homogeneous chemiluminescence determination kit and a quantitative determination method of pepsinogen I. The kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 comprises a luminescence donor molecule coupled with a first antibody of pepsinogen I and a reaction buffer solution; and the R2 reagent comprises a light-emitting receptor molecule coupled with a pepsinogen I second antibody and a reaction buffer solution. A donor / receptor double-labeled antibody sandwich reaction is adopted, one-step incubation is achieved, solid-phase separation and washing are not needed, the process is remarkably simplified, and the detection time is shortened; by collecting the luminous intensity at 620 nm and 665 nm and quantifying the luminous intensity by a specific value signal, errors caused by sample turbidity, color and volume fluctuation and instrument drift can be effectively corrected; meanwhile, a protein blocking agent, a chelating agent and a heterophilic antibody blocking component are introduced into a reaction buffer system, interference of non-specific adsorption and rheumatoid factors / heterophilic antibodies is reduced, and adaptability to complex matrixes such as bile fluid and serum / plasma is enhanced.

The application provides a PGII monoclonal antibody combination for detecting pepsinogen II and application thereof, the PGII monoclonal antibody combination for detecting pepsinogen II comprises a first antibody and a second antibody, the first antibody comprises a first light chain variable region and a first heavy chain variable region, and the second antibody comprises a second light chain variable region and a second heavy chain variable region. The monoclonal antibody combination can improve the sensitivity and accuracy of in vitro detection.

This invention discloses the application of a traditional Chinese medicine composition in the preparation of drugs for the prevention and treatment of gastritis. The composition comprises the following ingredients: Astragalus membranaceus, ginseng, Atractylodes macrocephala, fermented Cordyceps militaris powder, Lycium barbarum, Hedyotis diffusa, Fagopyrum dibotrys, Bistorta officinalis, Panax notoginseng, and Caesalpinia sappan. This invention is the first to discover and confirm that this traditional Chinese medicine composition can be used to prevent or treat chronic gastritis, especially chronic atrophic gastritis. Experiments have verified that it can significantly prevent or improve the pathological state of the gastric mucosa in rats with chronic atrophic gastritis. Specifically, it can significantly increase the serum pepsinogen I / II ratio, decrease gastrin-17 levels, reverse gastric gland atrophy, and repair the morphological structure of the gastric mucosa, achieving a systematic repair of the function and structure of the CAG gastric mucosa. Furthermore, the ingredients in this traditional Chinese medicine composition are rationally combined, and no obvious toxic side effects were observed under experimental conditions, demonstrating good safety and potential for long-term use.

The invention relates to the technical field of biological detection, and particularly discloses a joint detection kit for pepsinogen I and pepsinogen II and application of the joint detection kit. The pepsinogen I and pepsinogen II combined detection kit comprises a sample pad, a combination pad, a coating film and a water absorption pad, the coating film is an NC film coating antibody; the preparation method of the conjugate pad comprises the following steps: treating the fiber membrane with a pretreatment solution, drying, and then spraying a time-resolved fluorescent microsphere labeled antibody; the pretreatment solution is a solution with the pH value of 8.0 to 8.4, 8 to 12 mM of BS, 0.8 to 1.2 percent of BSA, 0.8 to 1.2 percent of PEG 4000, 0.02 to 0.03 percent of a surfactant and 4 to 6 percent of cane sugar. The pepsinogen I / pepsinogen II is subjected to joint detection by using the detection kit and the detection method provided by the invention, and the sensitivity, the accuracy and the repeatability are relatively high.

The application provides a monoclonal antibody against human pepsinogen I and an application thereof, and relates to the technical field of biotechnology.The monoclonal antibody against human pepsinogen I provided by the application has high specificity and sensitivity.A kit prepared by using the monoclonal antibody has good correlation with an international benchmark product Abbott PGI detection kit, and the kit makes up for the defect of poor matching degree between an antibody and an international benchmark detection system in the prior art, and has good clinical application value.

The invention relates to a chemiluminescence kit for detecting pepsinogen I. The chemiluminescence kit comprises an enzyme marker, a luminescent substrate solution and an anti-interference buffer system, the anti-interference buffer system comprises a nonionic surfactant, animal-derived IgG (immunoglobulin G), an antioxidant and catalase; the chemiluminescence kit also comprises a PGI calibration product and a PGI quality control product. The core active component of the enzyme marker is beta-galactosidase. The enzyme marker further comprises an anti-PGI monoclonal antibody marked by beta-galactosidase, bovine serum albumin, trehalose, cane sugar, magnesium chloride, sodium chloride, Proclin300 and PBS (Phosphate Buffer Solution). According to the kit, on the basis of the advantages of a spatial proximity method luminescence analysis method, a brand new anti-interference buffer system is introduced, so that the resistance of the kit to clinical common sample mechanism effects (such as hemolysis, lipemia, jaundice and heterotropism antibodies) is remarkably improved, and a detection result is more accurate and reliable in a complex real clinical sample.

This application provides a PGI monoclonal antibody combination for the detection of pepsinogen I and its application. The PGI monoclonal antibody combination for the detection of pepsinogen I includes a first antibody and a second antibody. The first antibody includes a first light chain variable region and a first heavy chain variable region, and the second antibody includes a second light chain variable region and a second heavy chain variable region. The amino acid sequences of the first light chain variable region include VL-CDR1-3 as shown in SEQ ID NO:1-3; the amino acid sequences of the first heavy chain variable region include VH-CDR1-3 as shown in SEQ ID NO:4-6; the amino acid sequences of the second light chain variable region include VL-CDR1-3 as shown in SEQ ID NO:7-9; and the amino acid sequences of the second heavy chain variable region include VH-CDR1-3 as shown in SEQ ID NO:10-12. This monoclonal antibody combination can improve the sensitivity and accuracy of in vitro detection.

This invention relates to a fermentation method for recombinant porcine pepsinogen A (rPGA). The method involves high-density fermentation of recombinant Pichia pastoris containing a porcine pepsinogen encoding gene. During the induction expression phase, the temperature is controlled at 19-23°C and the pH at 5.5-6.0, and a fed-batch solution containing methanol and sorbitol is used. The mass ratio of methanol to sorbitol in the fed-batch solution is 0.3-1.6:1. This fermentation method significantly improves protein expression levels and stability. The resulting recombinant porcine pepsinogen A (rPGA) exhibits stable quality, high enzyme activity, no active precursors, is not easily degraded, and poses no risk of pathogenic microorganism residue, demonstrating high safety and applicability in the biomedical field.